Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00296-020-04629-x http://scihub22266oqcxt.onion/10.1007/s00296-020-04629-x C7353833!7353833 !32654078     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32654078 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 259.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 259.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32654078 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Rheumatol+Int 2020 ; 40 (9 ): 1353-1360 Nephropedia Template TP {{tp|p=32654078 |t=2020. Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes |pdf=|usr=}}{{32654078 }} gab.com Text Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes JO: Rheumatol Int http://www.kidney.de/pget.php?&tw=1&pmid=32654078 #FOAvip As of June 10th 2020 about 7.2 million individuals have tested positive for, and more than 410,000 have died due to COVID-19. In this review we outline the pathophysiology that underpins the potential use of anti-rheumatic therapies for severe COVID-19 infection and summarize the current evidence regarding the risk and outcome of COVID-19 in patients with systemic autoimmune diseases. Thus far there is no convincing evidence that any disease-modifying anti-rheumatic drug (conventional synthetic, biologic or targeted synthetic) including hydroxychloroquine, may protect against severe COVID-19 infection; answers about their possible usefulness in the management of the cytokine storm associated with severe COVID-9 infection will only arise from ongoing randomized controlled trials. Evidence on COVID-19 risk and outcome in patients with systemic autoimmune diseases is extremely limited; thus, any conclusions would be unsafe and should be seen with great caution. At present, the risk and severity (hospitalization, intensive care unit admission and death) of COVID-19 infection in people with autoimmune diseases do not appear particularly dissimilar to the general population, with the possible exception of hospitalization in patients exposed to high glucocorticoid doses. At this stage it is impossible to draw any conclusions for differences in COVID-19 risk and outcome between different autoimmune diseases and between the various immunomodulatory therapies used for them. More research in the field is obviously required, including as a minimum careful and systematic epidemiology and appropriately controlled clinical trials. Twit Text FOAVip Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes ????Rheumatol Int http://www.kidney.de/pget.php?&tw=1&pmid=32654078 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32654078 #FOAvip English Wikipedia <ref>{{Cite pmid|32654078 }}</ref> Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes #MMPMID32654078 Kastritis E ; Kitas GD ; Vassilopoulos D ; Giannopoulos G ; Dimopoulos MA ; Sfikakis PP Rheumatol Int 2020[Sep]; 40 (9 ): 1353-1360 PMID32654078 show ga As of June 10th 2020 about 7.2 million individuals have tested positive for, and more than 410,000 have died due to COVID-19. In this review we outline the pathophysiology that underpins the potential use of anti-rheumatic therapies for severe COVID-19 infection and summarize the current evidence regarding the risk and outcome of COVID-19 in patients with systemic autoimmune diseases. Thus far there is no convincing evidence that any disease-modifying anti-rheumatic drug (conventional synthetic, biologic or targeted synthetic) including hydroxychloroquine, may protect against severe COVID-19 infection; answers about their possible usefulness in the management of the cytokine storm associated with severe COVID-9 infection will only arise from ongoing randomized controlled trials. Evidence on COVID-19 risk and outcome in patients with systemic autoimmune diseases is extremely limited; thus, any conclusions would be unsafe and should be seen with great caution. At present, the risk and severity (hospitalization, intensive care unit admission and death) of COVID-19 infection in people with autoimmune diseases do not appear particularly dissimilar to the general population, with the possible exception of hospitalization in patients exposed to high glucocorticoid doses. At this stage it is impossible to draw any conclusions for differences in COVID-19 risk and outcome between different autoimmune diseases and between the various immunomodulatory therapies used for them. More research in the field is obviously required, including as a minimum careful and systematic epidemiology and appropriately controlled clinical trials. |Antibodies, Monoclonal, Humanized/therapeutic use [MESH] |Antirheumatic Agents/*therapeutic use [MESH] |Autoimmune Diseases/*drug therapy/epidemiology/immunology [MESH] |Betacoronavirus [MESH] |COVID-19 [MESH] |COVID-19 Drug Treatment [MESH] |Comorbidity [MESH] |Coronavirus Infections/*drug therapy/epidemiology/immunology [MESH] |Cytokine Release Syndrome/*drug therapy/immunology [MESH] |Humans [MESH] |Janus Kinase Inhibitors/therapeutic use [MESH] |Pandemics [MESH] |Pneumonia, Viral/*drug therapy/epidemiology/immunology [MESH] |Risk Factors [MESH] |SARS-CoV-2 [MESH] |Severity of Illness Index [MESH]Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infec(epmc).pdf DeepDyve Pubget Overpricing